Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope

Vaccine

Volumn 33, Issue 2, 2015, Pages 298-306

  Zhu, Ye ^a   Jiang, Janina ^b   Said Sadier, Najwane ^a,c   Boxx, Gale ^b   Champion, Cheryl ^b   Tetlow, Ashley ^b   Kickhoefer, Valerie A ^b   Rome, Leonard H ^b   Ojcius, David M ^a   Kelly, Kathleen A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BEIRUT ARAB UNIVERSITY   (Lebanon)

Author keywords

Chlamydia; Inflammasomes; Lysosomes; Vaults

Indexed keywords

BACTERIAL VACCINE; CATHEPSIN B; CD4 ANTIGEN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MEMBRANE PROTEIN; NANOPARTICLE; POLYMORPHIC MEMBRANE PROTEIN G VAULT VACCINE; PROTEIN KINASE SYK; RECOMBINANT VACCINE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VAULT NANOPARTICLE; CARRIER PROTEIN; EPITOPE; IMMUNOLOGICAL ADJUVANT; NLRP3 PROTEIN, MOUSE; OUTER MEMBRANE PROTEIN; PMPG PROTEIN, CHLAMYDIA TRACHOMATIS; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SYK PROTEIN, HUMAN; SYK PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL STIMULATION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE LOSS; GENE PRODUCT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SECRETION; RNA INTERFERENCE; VACCINATION; WESTERN BLOTTING; ANIMAL; CD4+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; METABOLISM; MONOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CARRIER PROTEINS; CASPASE 1; CATHEPSIN B; CD4-POSITIVE T-LYMPHOCYTES; CHLAMYDIA TRACHOMATIS; EPITOPES; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOSOMES; MICE; MONOCYTES; NANOPARTICLES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEIN-TYROSINE KINASES; SYK KINASE;

EID: 84922360493     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.028     Document Type: Article

References (53)

1. Haggerty C.L., Gottlieb S.L., Taylor B.D., Low N., Xu F., Ness R.B. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010, 201. S134-S155.
2. Westrom L. Effect of acute pelvic inflammatory disease on fertility. Obstet Gynecol Surv 1975, 30:552-553.
3. Westrom L., Joesoef R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19:185-192.
4. Heinonen P.K., Miettinen A. Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 1994, 57:85-89.
5. Taylor B.D., Haggerty C.L. Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges. Infect Drug Resist 2011, 4:19-29.
6. Wiesenfeld H.C., Sweet R.L., Ness R.B., Krohn M.A., Amortegui A.J., Hillier S.L. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005, 32:400-405.
7. Morrison R.P., Feilzer K., Tumas D.B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995, 63:4661-4668.
8. Ito J.I., Lyons J.M. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect Immun 1999, 67:5518-5521.
9. Morrison S.G., Morrison R.P. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun 2001, 69:2643-2649.
10. Morrison S.G., Su H., Caldwell H.D., Morrison R.P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun 2000, 68:6979-6987.
11. Karunakaran K.P., Yu H., Foster L.J., Brunham R.C. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccin 2010, 6:676-680.
12. Su H., Feilzer K., Caldwell H.D., Morrison R.P. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun 1997, 65:1993-1999.
13. Ramsey K.H., Soderberg L.S., Rank R.G. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun 1988, 56:1320-1325.
14. Kickhoefer V.A., Poderycki M.J., Chan E.K.L., Rome L.H. The La RNA-binding protein interacts with the vault RNA and is a vault-associated protein. J Biol Chem 2002, 277:41282-41286.
15. Kedersha N.L., Rome L.H. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 1986, 103:699-709.
16. Kolli S., Zito C.I., Mossink M.H., Wiemer E.A., Bennett A.M. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem 2004, 279:29374-29385.
17. Yu Z., Fotouhi-Ardakani N., Wu L., Maoui M., Wang S., Banville D., et al. PTEN associates with the vault particles in HeLa cells. J Biol Chem 2002, 277:40247-40252.
18. Yi C., Li S., Chen X., Wiemer E.A., Wang J., Wei N., et al. Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cells. Cancer Res 2005, 65:5835-5840.
19. Steiner E., Holzmann K., Pirker C., Elbling L., Micksche M., Sutterluty H., et al. The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. J Cell Sci 2006, 119:459-469.
20. Kim E., Lee S., Mian M.F., Yun S.U., Song M., Yi K.S., et al. Crosstalk between Src and major vault protein in epidermal growth factor-dependent cell signalling. FEBS J 2006, 273:793-804.
21. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1:578-582.
22. Scheffer G.L., Schroeijers A.B., Izquierdo M.A., Wiemer E.A., Scheper R.J. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000, 12:550-556.
23. Gopinath S.C., Matsugami A., Katahira M., Kumar P.K. Human vault-associated non-coding RNAs bind to mitoxantrone, a chemotherapeutic compound. Nucleic Acids Res 2005, 33:4874-4881.
24. Kowalski M.P., Dubouix-Bourandy A., Bajmoczi M., Golan D.E., Zaidi T., Coutinho-Sledge Y.S., et al. Host resistance to lung infection mediated by major vault protein in epithelial cells. Science 2007, 317:130-132.
25. Stephen A.G. Assembly of vault-like particles in insect cells expressing only the major vault protein. J Biol Chem 2001, 276:23217-23220.
26. Kar U.K., Jiang J., Champion C.I., Salehi S., Srivastava M., Sharma S., et al. Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice. PLOS ONE 2012, 7:e38553.
27. Buehler D.C., Marsden M.D., Shen S.H., Toso D.B., Wu X., Loo J.A., et al. Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 2014, 8:7723-7732.
28. Berger W., Steiner E., Grusch M., Elbling L., Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 2009, 66:43-61.
29. Champion C.I., Kickhoefer V.A., Liu G., Moniz R.J., Freed A.S., Bergmann L.L., et al. A vault nanoparticle vaccine induces protective mucosal immunity. PLOS ONE 2009, 4:e5409.
30. Ogura Y., Sutterwala F.S., Flavell R.A. The inflammasome first line of the immune response to cell stress. Cell 2006, 126:659-662.
31. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2006, 14:10-22.
32. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
33. Allen I.C., Scull M.A., Moore C.B., Holl E.K., McElvania-TeKippe E., Taxman D.J., et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009, 30:556-565.
34. Munoz-Planillo R., Franchi L., Miller L.S., Nunez G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 2009, 183:3942-3948.
35. Saïd-Sadier N., Ojcius D.M. Alarmins, inflammasomes and immunity. Biomed J 2012, 35:437-449.
36. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 2008, 9:857-865.
37. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
38. Duncan J.A., Gao X., Huang M.T., O'Connor B.P., Thomas C.E., Willingham S.B., et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009, 182:6460-6469.
39. Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327.
40. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
41. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
42. Ciraci C., Janczy J.R., Sutterwala F.S., Cassel S.L. Control of innate and adaptive immunity by the inflammasome. Microbes Infect 2012, 14:1263-1270.
43. Moayeri M., Sastalla I., Leppla S.H. Anthrax and the inflammasome. Microbes Infect 2012, 14:392-400.
44. Shimada K., Crother T.R., Arditi M. Innate immune responses to Chlamydia pneumoniae infection: role of TLRs, NLRs, and the inflammasome. Microbes Infect 2012, 14:1301-1307.
45. Kickhoefer V.A., Siva A.C., Kedersha N.L., Inman E.M., Ruland C., Streuli M., et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999, 146:917-928.
46. Poderycki M.J., Kickhoefer V.A., Kaddis C.S., Raval-Fernandes S., Johansson E., Zink J.I., et al. The vault exterior shell is a dynamic structure that allows incorporation of vault-associated proteins into its interior. Biochemistry 2006, 45:12184-12193.
47. Kickhoefer V.A., Han M., Raval-Fernandes S., Poderycki M.J., Moniz R.J., Vaccari D., et al. Targeting vault nanoparticles to specific cell surface receptors. ACS Nano 2009, 3:27-36.
48. Maxion H.K., Liu W., Chang M.-H., Kelly K.A. The infecting dose of Chlamydia muridarum modulates the innate immune response and ascending infection. Infect Immun 2004, 72:6330-6340.
49. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis. J Biol Chem 1997, 272:17907-17911.
50. Kayagaki N., Warming S., Lamkanfi M., Walle L.V., Louie S., Dong J., et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011, 479:117-121.
51. Ng G., Sharma K., Ward S.M., Desrosiers M.D., Stephens L.A., Schoel W.M., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008, 29:807-818.
52. Xu S., Huo J., Gunawan M., Su I.-H., Lam K.-P. Activated dectin-1 localizes to lipid raft microdomains for signaling and activation of phagocytosis and cytokine production in dendritic cells. J Biol Chem 2009, 284:22005-22011.
53. Mócsai A., Ruland J., Tybulewicz V.L.J. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010, 10:387-402.